File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.18632/oncotarget.16171
- Scopus: eid_2-s2.0-85017509589
- WOS: WOS:000399819700127
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer
Title | Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer |
---|---|
Authors | |
Keywords | Biomarker CRC MiR-139-3p MiR-622 MiRNA |
Issue Date | 2017 |
Publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html |
Citation | Oncotarget, 2017, v. 8 n. 16, p. 27393-27400 How to Cite? |
Abstract | Aberrant levels of circulating microRNAs are potential biomarkers for the early detection of colorectal cancer. The aim of this study was to study miR-139-3p and miR-622 in serum as a non-invasive biomarker for colorectal cancer diagnosis. We applied quantitative polymerase chain reaction to determine the levels of miR-139-3p and miR-622 in 42 pairs of tumor and adjacent non-tumor tissues, and in serum samples of 117 patients and 90 control subjects. Our results showed that miR-139-3p was silenced whereas miR-622 was overexpressed in colorectal cancer. Similarly, serum miR-139-3p level was significantly lower in colorectal cancer patients than in control subjects whereas miR-622 was more frequently detectable in patients. ROC analysis showed that AUC of miR-139-3p was 0.9935, with a sensitivity of 96.6% and specificity of 97.8%. Serum miR-139-3p level showed high sensitivity and specificity for both early and late stage CRCs and proximal and distal CRCs. Detectable serum miR-622 showed a sensitivity of 87.5% and specificity of 63.5% for discriminating CRC patients, but the sensitivity dropped for late stage patients (72.7%). We also included analyses of the blood CEA level for comparing the diagnostic performance of these blood-based biomarkers. The median level in CRC patients (3.6 ng/ml) was significantly higher than that in control (1.8 ng/ml). The AUC value of CEA in diagnosing CRC patients was 0.7515. CEA showed a positive correlation with tumor stage and age of patients and its level was higher in male. Collectively, serum miR-139-3p has strong potential as a promising non-invasive biomarker in colorectal cancer detection. |
Persistent Identifier | http://hdl.handle.net/10722/243158 |
ISSN | 2016 Impact Factor: 5.168 2023 SCImago Journal Rankings: 0.789 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, L | - |
dc.contributor.author | Wan, TMH | - |
dc.contributor.author | Man, HW | - |
dc.contributor.author | Chow, KM | - |
dc.contributor.author | Lyer, D | - |
dc.contributor.author | Chen, G | - |
dc.contributor.author | Yau, TCC | - |
dc.contributor.author | Lo, OSH | - |
dc.contributor.author | Foo, CC | - |
dc.contributor.author | Poon, TCJ | - |
dc.contributor.author | Leung, WK | - |
dc.contributor.author | Pang, RWC | - |
dc.contributor.author | Law, WL | - |
dc.date.accessioned | 2017-08-25T02:50:51Z | - |
dc.date.available | 2017-08-25T02:50:51Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Oncotarget, 2017, v. 8 n. 16, p. 27393-27400 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/10722/243158 | - |
dc.description.abstract | Aberrant levels of circulating microRNAs are potential biomarkers for the early detection of colorectal cancer. The aim of this study was to study miR-139-3p and miR-622 in serum as a non-invasive biomarker for colorectal cancer diagnosis. We applied quantitative polymerase chain reaction to determine the levels of miR-139-3p and miR-622 in 42 pairs of tumor and adjacent non-tumor tissues, and in serum samples of 117 patients and 90 control subjects. Our results showed that miR-139-3p was silenced whereas miR-622 was overexpressed in colorectal cancer. Similarly, serum miR-139-3p level was significantly lower in colorectal cancer patients than in control subjects whereas miR-622 was more frequently detectable in patients. ROC analysis showed that AUC of miR-139-3p was 0.9935, with a sensitivity of 96.6% and specificity of 97.8%. Serum miR-139-3p level showed high sensitivity and specificity for both early and late stage CRCs and proximal and distal CRCs. Detectable serum miR-622 showed a sensitivity of 87.5% and specificity of 63.5% for discriminating CRC patients, but the sensitivity dropped for late stage patients (72.7%). We also included analyses of the blood CEA level for comparing the diagnostic performance of these blood-based biomarkers. The median level in CRC patients (3.6 ng/ml) was significantly higher than that in control (1.8 ng/ml). The AUC value of CEA in diagnosing CRC patients was 0.7515. CEA showed a positive correlation with tumor stage and age of patients and its level was higher in male. Collectively, serum miR-139-3p has strong potential as a promising non-invasive biomarker in colorectal cancer detection. | - |
dc.language | eng | - |
dc.publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html | - |
dc.relation.ispartof | Oncotarget | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Biomarker | - |
dc.subject | CRC | - |
dc.subject | MiR-139-3p | - |
dc.subject | MiR-622 | - |
dc.subject | MiRNA | - |
dc.title | Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer | - |
dc.type | Article | - |
dc.identifier.email | Ng, L: luing@hku.hk | - |
dc.identifier.email | Wan, TMH: tmhwan@hku.hk | - |
dc.identifier.email | Man, HW: johnnyb@hku.hk | - |
dc.identifier.email | Chow, KM: chowakm@hku.hk | - |
dc.identifier.email | Chen, G: guanghua@hku.hk | - |
dc.identifier.email | Yau, TCC: tyaucc@hku.hk | - |
dc.identifier.email | Lo, OSH: oswens@hku.hk | - |
dc.identifier.email | Foo, CC: ccfoo@hku.hk | - |
dc.identifier.email | Poon, TCJ: tcjensen@hku.hk | - |
dc.identifier.email | Leung, WK: hku75407@hku.hk | - |
dc.identifier.email | Pang, RWC: robertap@hku.hk | - |
dc.identifier.email | Law, WL: lawwl@hkucc.hku.hk | - |
dc.identifier.authority | Ng, L=rp02207 | - |
dc.identifier.authority | Yau, TCC=rp01466 | - |
dc.identifier.authority | Foo, CC=rp01899 | - |
dc.identifier.authority | Poon, TCJ=rp01603 | - |
dc.identifier.authority | Leung, WK=rp01479 | - |
dc.identifier.authority | Pang, RWC=rp00274 | - |
dc.identifier.authority | Law, WL=rp00436 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.18632/oncotarget.16171 | - |
dc.identifier.scopus | eid_2-s2.0-85017509589 | - |
dc.identifier.hkuros | 273711 | - |
dc.identifier.volume | 8 | - |
dc.identifier.issue | 16 | - |
dc.identifier.spage | 27393 | - |
dc.identifier.epage | 27400 | - |
dc.identifier.isi | WOS:000399819700127 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1949-2553 | - |